Abstract
Summary: Small cell lung cancer (SCLC) has demonstrated modest responses to immune-checkpoint blockade despite harboring a high mutational burden. In this issue, Sen and colleagues show remarkable synergy between inhibition of the DNA-damage response and the PD-1 axis, resulting in striking tumor regressions in SCLC mouse models.
See related article by Sen et al., p. 646.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
May 2019
Volume 9, Issue 5
Volume 9, Issue 5
Delivering a STINGing Blow to Small Cell Lung Cancer via Synergistic Inhibition of DNA-Damage Response and Immune-Checkpoint Pathways
Jump to section
- Article
- Abstract
- The Current State of Immunotherapy in Small Cell Lung Cancer
- Synergism between DNA-Damage Response and Immune-Checkpoint Inhibition
- Is Activation of Innate Immunity in Tumor Cells the New Synthetic Lethality for SCLC and Other Tumor Types?
- Disclosure of Potential Conflicts of Interest
- Acknowledgments
- References
- Figures & Data
- Info & Metrics
Advertisement